miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F19%3A00108622" target="_blank" >RIV/00216224:14740/19:00108622 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-1800" target="_blank" >http://dx.doi.org/10.1158/1538-7445.AM2019-1800</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-1800" target="_blank" >10.1158/1538-7445.AM2019-1800</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
Popis výsledku v původním jazyce
Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
Název v anglickém jazyce
miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
Popis výsledku anglicky
Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/NV18-03-00554" target="_blank" >NV18-03-00554: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů